https://www.aigom.it/wp-content/uploads/2025/09/ART23.9.png14361087Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-09-23 07:52:332025-09-23 07:52:33SURVIVAL OF PATIENTS WITH LUNG ADENOCARCINOMA DIAGNOSED IN 2000, 2010, AND 2020.
https://www.aigom.it/wp-content/uploads/2025/09/ART169.png1197793Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-09-16 10:06:042025-09-16 10:06:04PLATELET TRANSFUSION: 2025 AABB AND ICTMG INTERNATIONAL CLINICAL PRACTICE GUIDELINES.
https://www.aigom.it/wp-content/uploads/2025/09/articolo9settembre.png1216849Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-09-09 07:56:122025-09-09 07:56:12TRASTUZUMAB DERUXTECAN (T-DXd)+PERTUZUMAB (P) vs TAXANE+TRASTUZUMAB+PERTUZUMAB (THP) FOR FIRST-LINE (1L) TREATMENT OF PATIENTS (pts) WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE (HER2+) ADVANCED/METASTATIC BREAST CANCER (a/mBC): INTERIM RESULTS FROM DESTINY-BREAST09
https://www.aigom.it/wp-content/uploads/2025/09/ART2SETTEMBRE.png12881109Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-09-02 07:05:482025-09-02 07:05:48PERIOPERATIVE DURVALUMAB IN GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER.
https://www.aigom.it/wp-content/uploads/2025/07/ART15LUGLIO.png1315960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-07-14 07:49:272025-07-14 07:49:27ENCORAFENIB, CETUXIMAB, AND mFOLFOX6 IN BRAF-MUTATED COLORECTAL CANCER.
https://www.aigom.it/wp-content/uploads/2025/07/ART8LUGLIO.png1349960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-07-08 08:31:402025-07-08 08:31:40FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTETRNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY.
https://www.aigom.it/wp-content/uploads/2025/07/ART1LUGLIO.png1146960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-07-01 08:46:042025-07-01 08:46:04ELIZANENTANT FOR VASOMOTOR SYMPTOMS FROM ENDOCRINE THERAPY FOR BREAST CANCER
https://www.aigom.it/wp-content/uploads/2025/06/ART24.6.png1272888Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-06-23 08:16:072025-06-23 08:16:07ZOLBETUXIMAB PLUS mFOLFOX6 IN PATIENTS WITH CLDN18.2-positive, HER2-negative, UNTREATED, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION ADENOCARCINOMA (SPOTLIGHT): A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 TRIAL.
https://www.aigom.it/wp-content/uploads/2025/06/ART3.6.png1350960Luisahttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngLuisa2025-06-03 07:58:002025-06-03 07:58:00DATOPOTAMAB DERUXTECAN IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH ACTIONABLE GENOMIC ALTERATIONS: RESULTS FROM THE PHASE II TROPION-Lung05 STUDY.
